![](/cdn/assets/images/search/clock.png)
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Ibex Technologies Inc | TSXV:IBT | TSX Venture | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 1.44 | 1.25 | 1.45 | 0 | 01:00:00 |
IBEX Technologies Inc. (TSX VENTURE:IBT) today announces the grant of options to Richard Collin, CPA, CA, its newly appointed Director of Finance. In connection with his appointment, Mr. Collin has been granted options to acquire up to 50,000 common shares of IBEX at an exercise price of $0.08 per common share for a term of 10 years pursuant to IBEX's incentive stock option plan. ABOUT IBEX The Company, through its wholly owned subsidiaries, IBEX Pharmaceuticals Inc. (Montreal, QC) and Bio-Research Products Inc. (North Liberty, IA), manufactures and markets enzymes for biomedical use. IBEX also manufactures and markets a series of arthritis assays which are widely used in osteoarthritis research. For more information, please visit the Company's website at www.ibex.ca. Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. FOR FURTHER INFORMATION PLEASE CONTACT: IBEX Technologies Inc. Paul Baehr President & CEO 514-344-4004 x 143 www.ibex.ca
1 Year Ibex Technologies Chart |
1 Month Ibex Technologies Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions